SANTA CRUZ — The fight to save the Catalyst Club in downtown Santa Cruz is still going strong, despite the failure of a recent petition effort. Local entrepreneurs Jeremy Stone and Jay Brown are ...

This month, KTAR’s Community Spotlight is highlighting the work Barrow Neurological Institute does to empower stroke survivors in Arizona. With May recognized as Stroke Awareness Month, Barrow doctors ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...

Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...

Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals (CPRX) for $31.50 per share in cash, for a total equity value of approximately $4.1B. The deal has been ...

State-backed CDP Equity to have a stake in combined entity Deal comes after Chiesi's $1.9 billion buyout of U.S. KalVista Angelini aims to create global player in rare disease drugs ROME/MILAN, May 7 ...

Angelini Pharma is putting up $4.1 billion in a play for Catalyst Pharmaceuticals, scooping up three rare disease drugs that will allow the Italian company to enter the U.S. market. Angelini believes ...

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration ...

Angelini Pharma will acquire Catalyst Pharmaceuticals in a $4.1 billion deal that hands the Italian drugmaker a portfolio of approved medicines for rare disorders of the central nervous system.